Hutch News

Hutch News

Stories tagged 'chimeric antigen receptor'

First systematic study of infections after CAR T-cell therapy

“Benchmark” research could help reduce complications of emerging immunotherapy

Nov. 6, 2017 | by Susan Keown / Fred Hutch News Service

The first detailed study of infections after CAR T-cell therapy could help researchers improve the safety of this emerging type of genetically engineered cell therapy for cancer.

View story >


Mourning the loss of Dr. Oliver 'Ollie' Press

Lymphoma physician-scientist, leader and mentor made lifesaving contributions to the development of targeted cancer therapies

Oct. 2, 2017 | by Susan Keown / Fred Hutch News Service

Dr. Oliver Press died of complications from glioma, a brain cancer. Press was a physician-scientist who made foundational contributions to the development of targeted therapies for blood cancers.

View story >


Forum at Fred Hutch focuses on the hottest developments in cancer immunotherapy

Immune-based treatments move from the fringes to the spotlight

June 16, 2017 | By Susan Keown / Fred Hutch News Service

What's new in cancer immunotherapy? Five hot topics, from new combination therapies to cost.

View story >


Dissolving implant could bring immunotherapy to solid tumors

A biopolymer sponge delivers cancer-shrinking T-cell therapy in preclinical study

April 24, 2017 | By Sabrina Richards / Fred Hutch News Service

A dissolving scaffold developed by Dr. Matthias Stephan delivers engineered anti-tumor immune cells to crowded masses of tumor cells and recruits the native immune system to mount a second-wave attack on the cancer.

View story >


Tiny tech reprograms immune cells to fight cancer

Nanoparticles turn immune cells into leukemia-fighting powerhouses while they’re still inside the body

April 17, 2017 | By Sabrina Richards / Fred Hutch News Service

Dr. Matthias Stephan has designed nanoparticles that have the potential to make cellular immunotherapy quicker, cheaper, easier to administer and more widely available, by carrying anti-cancer genes to immune cells still inside the body.

View story >


Patients with advanced lymphoma in remission after T-cell therapy

New study: 7 of 11 trial participants who got two-drug combination chemo plus intermediate dose of engineered T cells went into complete remission

Sept. 7, 2016 | By Susan Keown / Fred Hutch News Service

Seven of 11 trial participants who got a two-drug combination chemo plus intermediate dose of engineered T cells went into complete remission, a new study found.

View story >



GIVE NOW &
SAVE LIVES

Support our quest for cures

Story Archive


Publications

Hutch Magazine
Our quarterly magazine

Annual Report
Fiscal year highlights

Science Spotlight
Monthly review of Center-authored papers



Fred Hutch News

        Get updates via email.